Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Stage III Ovarian Cancer AJCC v6 and v7
Stage IIIB Ovarian Cancer AJCC v6 and v7
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
Malignant Ovarian Brenner Tumor
Ovarian Seromucinous Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment

Registration Number: NCT00951496

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bevacizumab together with intravenous chemotherapy is more effective than giving bevacizumab together with intraperitoneal chemotherapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Detailed Description: PRIMARY OBJECTIVES:

I. To determine if one or both of the proposed intraperitoneal chemotherapy regimens improves the progression-free survival (PFS) event rate compared to standard intravenous chemotherapy for first-line treatment of patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer.

II. If both intraperitoneal (IP) regimens significantly improve the PFS event rate compared to the standard regimen, then a second study objective is to determine whether IP cisplatin and intravenous (IV) paclitaxel on day one plus IP paclitaxel on day eight improves the PFS event rate when compared to the IP carboplatin and IV paclitaxel.

SECONDARY OBJECTIVES:

I. To determine if intraperitoneal chemotherapy reduces the overall death rate compared to standard intravenous chemotherapy.

II. To assess the frequency and severity of adverse events as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.

III. To compare the patient-reported outcomes on: Quality of Life (Function Assessment of Cancer Therapy-Ovarian-Trial Outcome Index \[FACT-O-TOI\]), Neuropathy (FACT-Gynecologic Oncology Group/Neurotoxicity \[GOG/NTX4\] scale), Abdominal discomfort (FACT-GOG/AD scale), Fatigue (FACIT-Fatigue scale), and Nausea (item from FACT-O-TOI).

IV. To assess the frequency and the reasons for early discontinuation of the study treatments.

TERTIARY OBJECTIVES:

I. To bank deoxyribonucleic acid (DNA) from whole blood for research and examine the association between single nucleotide polymorphisms (SNPs) and measures of clinical outcome including overall survival, progression-free survival and adverse events.

II. To bank archival tumor for research and examine the association between tumor markers and measures of clinical outcome including overall survival, progression-free survival and adverse events.

III. Patients will be encouraged to enroll on the companion translational research protocol (CEM0703 under development).

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM I: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.

ARM III: Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 1560

Inclusion Criteria

Patients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, stage II, III, or IV with either optimal (=< 1 cm residual disease) or suboptimal residual disease; in the event of a higher priority Phase III Gynecologic Oncology Group (GOG) protocol becoming available for suboptimal and/or stage IV patients, the eligibility of this study will narrow and exclude those patients at those participating institutions (11/02/2009)
- Note: patients with suboptimal disease/and or stage IV will not be eligible as of April 1, 2011; they should be enrolled on GOG-0262 (03/14/11)
- All patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, with appropriate tissue for histologic evaluation; the minimum surgery required is an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking; if additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the GOG Surgical Procedures Manual (https://www.gog.fccc.edu/manuals/pdf/surgman.pdf) (11/02/2009)(08/16/2010)
Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.); however, the histologic features of the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma; if doubt exists, it is recommended that the investigator should have the slides reviewed by an independent pathologist prior to entry; patients may have co-existing endometrial cancer so long as the primary origin of invasive tumor is ovarian or peritoneal; Note: patients with mucinous, low grade and clear cell disease are eligible unless there is a higher priority GOG trial open (11/02/2009) (08/16/2010)
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl, equivalent to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factors
Platelets greater than or equal to 100,000/mcl
Creatinine no greater than institutional upper limits of normal (03/29/10)
Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE grade 1)
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than or equal to 2.5 x ULN (CTCAE grade 1)
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)
Neuropathy (sensory and motor) less than or equal to CTCAE grade 1
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 times the upper limit of normal (heparin, Lovenox or alternative anticoagulants are acceptable); this corresponds to CTCAE version 3.0 grade 1 one or less (11/02/2009) (03/29/10)
Patients with a GOG performance status of 0, 1, or 2
Patients must be entered and treated within 12 weeks of their most recent surgery performed for the combined purpose of diagnosis, staging and/or cytoreduction; the first cycle of chemotherapy should not be given until at least seven days after the most recent major surgery, which allows 4 weeks to have elapsed prior to the first bevacizumab dose; (placement of venous or peritoneal access devices will be considered minor surgery) (03/29/10)
Patients who have met the pre-entry requirements specified
An approved informed consent and authorization permitting release of personal health information must be signed by the patient or guardian
Patients in this trial may receive ovarian estrogen +/- progestin replacement therapy as indicated at the lowest effective dose(s) for control of menopausal symptoms at any time, but high dose progestin as an appetite stimulant should be avoided (03/29/10)

Exclusion Criteria

Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly "tumors of low malignant potential") or recurrent invasive epithelial ovarian cancer treated with surgery only (such as those with stage IA or IB low grade lesions) are not eligible; patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies are excluded if there is any evidence of the other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy (11/02/2009)
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior chemotherapy for any abdominal or pelvic tumor including neo-adjuvant chemotherapy for their ovarian or primary peritoneal cancer are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
Patients who have received any targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian or peritoneal primary cancer
Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than IB; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO grade 3 lesions
Patients with acute hepatitis or active infection that requires parenteral antibiotics
Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
Patients with history or evidence upon physical examination of major central nervous system (CNS) disease (for example: primary brain tumor, metastatic cancer in the brain, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident [CVA, stroke], transient ischemic attack [TIA] or subarachnoid hemorrhage within six months of the first date of treatment on this study) (11/02/2009) (03/29/10)
Patients with clinically significant cardiovascular disease; this includes:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mmHg
- Myocardial infarction or unstable angina < 6 months prior to registration
- New York Heart Association (NYHA) grade II or greater congestive heart failure
- Serious cardiac arrhythmia requiring medication; this does not include asymptomatic atrial fibrillation with controlled ventricular rate, or past history of supraventricular tachycardia controlled with medications and that is asymptomatic (03/29/10)
- CTCAE grade 2 or greater peripheral vascular disease (at least brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit)
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies; patients with known allergy to Cremophor or polysorbate 80
Patients with clinically significant proteinuria; urine protein should be screened by urine protein-creatinine ratio (UPCR); patients must have a UPCR < 1.0 to allow participation in the study
Patients with or with anticipation of invasive procedures as defined below:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab therapy (cycle 2)
- Major surgical procedure anticipated during the course of the study; this includes, but is not limited to abdominal surgery (laparotomy or laparoscopy) prior to disease progression, such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery
- Core biopsy, within 7 days prior to the first date of bevacizumab therapy (cycle 2)
Patients with GOG performance grade of 3 or 4
Patients who are pregnant or nursing; patients of childbearing potential must agree to use contraceptive measures during study therapy and for at least six months after completion of bevacizumab therapy
Patients who have received prior therapy with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumab
Patients with clinical symptoms or signs of gastrointestinal obstruction and/ or those who require parenteral hydration and/or nutrition; patients with history or current diagnosis of inflammatory bowel disease are not eligible (12/20/10)
Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; examples of this would be: persistent gastrointestinal symptoms resulting from clostridia difficile enterocolitis or bowel surgery which may increase gastrointestinal toxicity from bevacizumab; or hearing loss or neuropathy which would prevent tolerance to cisplatin, and paclitaxel administration; the investigator should feel free to consult the Study Chair or Study Co-Chairs for uncertainty in this regard (12/20/10)
Patients with metastatic tumor in the parenchyma of the liver or lungs with proximity to large vessels which could make the patient as high risk of lethal hemorrhage during treatment with bevacizumab (i.e. hemoptysis, liver rupture) (11/02/2009)

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm III (paclitaxel IP, bevacizumab, cisplatin IP)	Laboratory Biomarker Analysis	Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm I (paclitaxel, carboplatin, bevacizumab)	Laboratory Biomarker Analysis	Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
Arm II (paclitaxel, bevacizumab, carboplatin IP)	Quality-of-Life Assessment	Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm I (paclitaxel, carboplatin, bevacizumab)	Bevacizumab	Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
Arm I (paclitaxel, carboplatin, bevacizumab)	Quality-of-Life Assessment	Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
Arm II (paclitaxel, bevacizumab, carboplatin IP)	Bevacizumab	Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm II (paclitaxel, bevacizumab, carboplatin IP)	Laboratory Biomarker Analysis	Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm III (paclitaxel IP, bevacizumab, cisplatin IP)	Bevacizumab	Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm III (paclitaxel IP, bevacizumab, cisplatin IP)	Quality-of-Life Assessment	Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm I (paclitaxel, carboplatin, bevacizumab)	Carboplatin	Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
Arm I (paclitaxel, carboplatin, bevacizumab)	Paclitaxel	Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
Arm II (paclitaxel, bevacizumab, carboplatin IP)	Carboplatin	Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm II (paclitaxel, bevacizumab, carboplatin IP)	Paclitaxel	Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm III (paclitaxel IP, bevacizumab, cisplatin IP)	Cisplatin	Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Arm III (paclitaxel IP, bevacizumab, cisplatin IP)	Paclitaxel	Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.

Primary Outcome Measures

Name	Time	Method
Median Progression-free Survival	Progression-free survival is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.	Estimate the median duration of progression-free survival in months. Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Secondary Outcome Measures

Name	Time	Method
Patient Reported Neurotoxicity (Ntx)	Time points: Baseline, prior to cycle 4, prior to cycle 7, prior to cycle 13, prior to cycle 21, 84 weeks post starting treatment	The FACT/GOG-NTX subscale (short version) contains 4 items measuring sensory neuropathy. Each item is scored using a 5 point Likert scale (0=not at all; 1=a little bit;2=somewhat;3=quite a bit; 4=very much). For each item, reversal was performed prior to score calculation so that a large score suggests less symptoms. According to the FACIT measurement system, the subscale score was calculated as the summation of the individual item scores if more than 50% of a subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The Ntx subscale score ranges from 0-16 with a large subscale score suggesting less symptom or better QOL.
Patient Reported Nausea	Time points: Baseline, prior to cycle 4, prior to cycle 7, prior to cycle 13, prior to cycle 21, 84 weeks post starting treatment	Nausea was measured with the a single item ,' I have nausea' from the FACT-O TOI, and was scored using a 5 point scale (0=not at all; 1=a little bit; 2=somewhat;3=quite a bit;4=very much)
Patient Reported Quality of Life (QOL)	Time points: Baseline, prior to cycle 4, prior to cycle 7, prior to cycle 13, prior to cycle 21, up to 84 weeks post starting treatment	QOL was measured with the FACT-O TOI score. Means at baseline are raw means. Scores are reported at all time points in the outcome measure table. FACT-O TOI is Trial outcome index (TOI) of the Functional assessment of cancer therapy (FACT) for ovarian cancer (FACT-O). The FACT-O TOI is composed of three subscales; Physical Well Being (PWB) ( 7 items), and Ovarian Cancer subscale (OCS) (12 items). Each item in the FACT-O TOI are scored using a 5 point scale (0=not at all; 1=a little bit; 2=somewhat;3=quite a bit;4=very much). A subscale score is computed as long as more thatn 50% of subscale items have been answered. A total score of the FACT-O items provide valid responses and all three subscales have valid scores. A score of the FACT-) TOI is ranged 0-104 with a larger score indicating a more preferred state of health-related quality of life (HRQOL).
Overall Survival	Up to 10 years	Estimate the median duration of overall survival in months.
Patients With Adverse Events by Treatment Group, as Defined by NCI CTCAE (Common Terminology Criteria for Adverse Events Version 3.0) Version 3.0	During treatment and up to 30 days after end of treatment	Eligible and treated patients. CTCAE includes grades 1-5. Grade refers to the severity of the adverse event. Grades 0 listed should be interpreted to mean there were no subjects in the arm with a toxicity to report. Grade 1 toxicities are mild; asymptomatic or mild symptoms. Grade 2 toxicities are moderate; minimal, local or noninvasive intervention indicated. Grade 3 toxicities are severe or medically significant but not immediately life-threatening. Grade 4 toxicities are life threatening. Grade 5 is death related to adverse event.
Patient Reported Fatigue	Time points: Baseline, prior to cycle 4, prior to cycle 7, prior to cycle 13, prior to cycle 21, 84 weeks post starting treatment	Patient reported fatigue as measured with the Functional Assessment of Chronic Illness Therapy- Fatigue scale (FACIT-Fatigue). The FACIT-Fatigue contains 13 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Fatigue score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The FACIT-Fatigue score ranges 0-52 with a large score suggesting less fatigue.

Trial Locations

Locations (500): Mayo Clinic in Arizona
🇺🇸
Scottsdale, Arizona, United States
Providence Alaska Medical Center
🇺🇸
Anchorage, Alaska, United States
The Hospital of Central Connecticut
🇺🇸
New Britain, Connecticut, United States
Eastern Connecticut Hematology and Oncology Associates
🇺🇸
Norwich, Connecticut, United States
Christiana Care Health System-Christiana Hospital
🇺🇸
Newark, Delaware, United States
Smilow Cancer Hospital Care Center at Saint Francis
🇺🇸
Hartford, Connecticut, United States
Danbury Hospital
🇺🇸
Danbury, Connecticut, United States
Beebe Medical Center
🇺🇸
Lewes, Delaware, United States
University of Mississippi Medical Center
🇺🇸
Jackson, Mississippi, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Jersey Shore Medical Center
🇺🇸
Neptune, New Jersey, United States
Benefis Healthcare- Sletten Cancer Institute
🇺🇸
Great Falls, Montana, United States
Edwards Comprehensive Cancer Center
🇺🇸
Huntington, West Virginia, United States
Mount Carmel Health Center West
🇺🇸
Columbus, Ohio, United States
Doctors Hospital
🇺🇸
Columbus, Ohio, United States
Illinois CancerCare-Havana
🇺🇸
Havana, Illinois, United States
Fox Chase Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
Case Western Reserve University
🇺🇸
Cleveland, Ohio, United States
West Penn Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
M D Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Swedish Medical Center-First Hill
🇺🇸
Seattle, Washington, United States
University of Washington Medical Center - Northwest
🇺🇸
Seattle, Washington, United States
The Watson Clinic
🇺🇸
Lakeland, Florida, United States
Hartford Hospital
🇺🇸
Hartford, Connecticut, United States
Morton Plant Hospital
🇺🇸
Clearwater, Florida, United States
University of South Alabama Mitchell Cancer Institute
🇺🇸
Mobile, Alabama, United States
City of Hope Comprehensive Cancer Center
🇺🇸
Duarte, California, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
🇺🇸
Burbank, California, United States
PCR Oncology
🇺🇸
Arroyo Grande, California, United States
John Muir Medical Center-Concord Campus
🇺🇸
Concord, California, United States
Kaiser Permanente Los Angeles Medical Center
🇺🇸
Los Angeles, California, United States
Alta Bates Summit Medical Center-Herrick Campus
🇺🇸
Berkeley, California, United States
UCLA / Jonsson Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States
Rocky Mountain Gynecologic Oncology PC
🇺🇸
Englewood, Colorado, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
🇺🇸
Orange, California, United States
Sutter Cancer Research Consortium
🇺🇸
Novato, California, United States
Palo Alto Medical Foundation-Gynecologic Oncology
🇺🇸
Mountain View, California, United States
Saint Vincent's Medical Center
🇺🇸
Jacksonville, Florida, United States
Sutter Solano Medical Center/Cancer Center
🇺🇸
Vallejo, California, United States
Stanford Cancer Institute Palo Alto
🇺🇸
Palo Alto, California, United States
John Muir Medical Center-Walnut Creek
🇺🇸
Walnut Creek, California, United States
Saint Joseph Hospital - Orange
🇺🇸
Orange, California, United States
Wilcox Memorial Hospital and Kauai Medical Clinic
🇺🇸
Lihue, Hawaii, United States
Sibley Memorial Hospital
🇺🇸
Washington, District of Columbia, United States
Stamford Hospital/Bennett Cancer Center
🇺🇸
Stamford, Connecticut, United States
Florida Gynecologic Oncology
🇺🇸
Fort Myers, Florida, United States
Southeast Gynecologic Oncology Associates
🇺🇸
Jacksonville, Florida, United States
Illinois CancerCare-Bloomington
🇺🇸
Bloomington, Illinois, United States
Kootenai Cancer Center
🇺🇸
Post Falls, Idaho, United States
Northside Hospital
🇺🇸
Atlanta, Georgia, United States
IU Health La Porte Hospital
🇺🇸
La Porte, Indiana, United States
Northeast Georgia Medical Center-Gainesville
🇺🇸
Gainesville, Georgia, United States
MedStar Washington Hospital Center
🇺🇸
Washington, District of Columbia, United States
Bayfront Outpatient Health Clinic
🇺🇸
Saint Petersburg, Florida, United States
John B Amos Cancer Center
🇺🇸
Columbus, Georgia, United States
Cancer Center of Kansas - Dodge City
🇺🇸
Dodge City, Kansas, United States
Cancer Center of Kansas-Liberal
🇺🇸
Liberal, Kansas, United States
Memorial Health University Medical Center
🇺🇸
Savannah, Georgia, United States
Illinois CancerCare-Kewanee Clinic
🇺🇸
Kewanee, Illinois, United States
Memorial Hospital of South Bend
🇺🇸
South Bend, Indiana, United States
University of Kansas Cancer Center
🇺🇸
Kansas City, Kansas, United States
Cancer Center of Kansas - Wellington
🇺🇸
Wellington, Kansas, United States
Ascension Via Christi Hospitals Wichita
🇺🇸
Wichita, Kansas, United States
Illinois CancerCare-Peoria
🇺🇸
Peoria, Illinois, United States
Illinois CancerCare-Pekin
🇺🇸
Pekin, Illinois, United States
Community Howard Regional Health
🇺🇸
Kokomo, Indiana, United States
Cotton O'Neil Cancer Center / Stormont Vail Health
🇺🇸
Topeka, Kansas, United States
Reid Health
🇺🇸
Richmond, Indiana, United States
Maine Medical Center-Bramhall Campus
🇺🇸
Portland, Maine, United States
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
🇺🇸
Baltimore, Maryland, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
Saint Elizabeth Medical Center South
🇺🇸
Edgewood, Kentucky, United States
McFarland Clinic PC - Ames
🇺🇸
Ames, Iowa, United States
Southwest Medical Center
🇺🇸
Liberal, Kansas, United States
Cancer Center of Kansas - Pratt
🇺🇸
Pratt, Kansas, United States
Cancer Center of Kansas - Winfield
🇺🇸
Winfield, Kansas, United States
Bronson Battle Creek
🇺🇸
Battle Creek, Michigan, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Massachusetts General Hospital Cancer Center
🇺🇸
Boston, Massachusetts, United States
Woman's Hospital
🇺🇸
Baton Rouge, Louisiana, United States
Harold Alfond Center for Cancer Care
🇺🇸
Augusta, Maine, United States
UMass Memorial Medical Center - Memorial Division
🇺🇸
Worcester, Massachusetts, United States
Christiana Care - Union Hospital
🇺🇸
Elkton, Maryland, United States
Lahey Hospital and Medical Center
🇺🇸
Burlington, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸
Boston, Massachusetts, United States
Associates in Oncology Hematology PC -Kensington
🇺🇸
Kensington, Maryland, United States
Medini, Eitan MD (UIA Investigator)
🇺🇸
Alexandria, Minnesota, United States
Essentia Health Cancer Center
🇺🇸
Duluth, Minnesota, United States
Saint John's Hospital - Healtheast
🇺🇸
Maplewood, Minnesota, United States
Metro Minnesota Community Oncology Research Consortium
🇺🇸
Saint Louis Park, Minnesota, United States
Saint Vincent Frontier Cancer Center
🇺🇸
Billings, Montana, United States
Queens Hospital Center
🇺🇸
Jamaica, New York, United States
Adena Regional Medical Center
🇺🇸
Chillicothe, Ohio, United States
Cone Health Cancer Center at Alamance Regional
🇺🇸
Burlington, North Carolina, United States
Upper Valley Medical Center
🇺🇸
Troy, Ohio, United States
Greene Memorial Hospital
🇺🇸
Xenia, Ohio, United States
Clements University Hospital
🇺🇸
Dallas, Texas, United States
Harrison Medical Center
🇺🇸
Bremerton, Washington, United States
Providence Regional Cancer Partnership
🇺🇸
Everett, Washington, United States
Northern Virginia Pelvic Surgery Associates
🇺🇸
Annandale, Virginia, United States
University of Pennsylvania/Abramson Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
University of Virginia Cancer Center
🇺🇸
Charlottesville, Virginia, United States
Peninsula Cancer Institute-Newport News
🇺🇸
Newport News, Virginia, United States
Utah Valley Regional Medical Center
🇺🇸
Provo, Utah, United States
Danville Regional Medical Center
🇺🇸
Danville, Virginia, United States
Women and Infants Hospital
🇺🇸
Providence, Rhode Island, United States
Cancer Care Northwest - Spokane South
🇺🇸
Spokane, Washington, United States
Dixie Medical Center Regional Cancer Center
🇺🇸
Saint George, Utah, United States
University of Vermont Medical Center
🇺🇸
Burlington, Vermont, United States
Vince Lombardi Cancer Clinic - Oshkosh
🇺🇸
Oshkosh, Wisconsin, United States
Kaiser Permanente Washington
🇺🇸
Seattle, Washington, United States
Sanford Cancer Center Oncology Clinic
🇺🇸
Sioux Falls, South Dakota, United States
Black Hills Obstetrics and Gynecology
🇺🇸
Rapid City, South Dakota, United States
Carilion Clinic Gynecological Oncology
🇺🇸
Roanoke, Virginia, United States
Fred Hutchinson Cancer Research Center
🇺🇸
Seattle, Washington, United States
Seattle Cancer Care Alliance
🇺🇸
Seattle, Washington, United States
Wenatchee Valley Hospital and Clinics
🇺🇸
Wenatchee, Washington, United States
University of Washington Medical Center - Montlake
🇺🇸
Seattle, Washington, United States
Aurora BayCare Medical Center
🇺🇸
Green Bay, Wisconsin, United States
Gundersen Lutheran Medical Center
🇺🇸
La Crosse, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Saint Mary's
🇺🇸
Green Bay, Wisconsin, United States
Indiana University/Melvin and Bren Simon Cancer Center
🇺🇸
Indianapolis, Indiana, United States
University of California San Diego
🇺🇸
San Diego, California, United States
Abbott-Northwestern Hospital
🇺🇸
Minneapolis, Minnesota, United States
Hennepin County Medical Center
🇺🇸
Minneapolis, Minnesota, United States
University of Minnesota/Masonic Cancer Center
🇺🇸
Minneapolis, Minnesota, United States
Good Samaritan Hospital - Cincinnati
🇺🇸
Cincinnati, Ohio, United States
California Pacific Medical Center-Pacific Campus
🇺🇸
San Francisco, California, United States
UCSF Medical Center-Mount Zion
🇺🇸
San Francisco, California, United States
Intermountain Health Care
🇺🇸
Salt Lake City, Utah, United States
Huntsman Cancer Institute/University of Utah
🇺🇸
Salt Lake City, Utah, United States
LDS Hospital
🇺🇸
Salt Lake City, Utah, United States
Pacific Cancer Institute of Maui
🇺🇸
Wailuku, Hawaii, United States
Cancer Center of Kansas-Independence
🇺🇸
Independence, Kansas, United States
Cancer Center of Kansas-Wichita Medical Arts Tower
🇺🇸
Wichita, Kansas, United States
Rocky Mountain Oncology
🇺🇸
Casper, Wyoming, United States
Associates In Womens Health
🇺🇸
Wichita, Kansas, United States
Wichita NCI Community Oncology Research Program
🇺🇸
Wichita, Kansas, United States
Cancer Center of Kansas - Chanute
🇺🇸
Chanute, Kansas, United States
Lawrence Memorial Hospital
🇺🇸
Lawrence, Kansas, United States
Cancer Center of Kansas - Wichita
🇺🇸
Wichita, Kansas, United States
Welch Cancer Center
🇺🇸
Sheridan, Wyoming, United States
Baystate Medical Center
🇺🇸
Springfield, Massachusetts, United States
Saint Joseph's Hospital and Medical Center
🇺🇸
Phoenix, Arizona, United States
University of Colorado
🇺🇸
Denver, Colorado, United States
Compass Oncology Rose Quarter
🇺🇸
Portland, Oregon, United States
Eastern Maine Medical Center
🇺🇸
Bangor, Maine, United States
University of Alabama at Birmingham Cancer Center
🇺🇸
Birmingham, Alabama, United States
University of Arizona Cancer Center-North Campus
🇺🇸
Tucson, Arizona, United States
University of Arkansas for Medical Sciences
🇺🇸
Little Rock, Arkansas, United States
Mills-Peninsula Medical Center
🇺🇸
Burlingame, California, United States
Marin General Hospital
🇺🇸
Greenbrae, California, United States
Long Beach Memorial Medical Center-Todd Cancer Institute
🇺🇸
Long Beach, California, United States
Sutter Roseville Medical Center
🇺🇸
Roseville, California, United States
Mayo Clinic in Florida
🇺🇸
Jacksonville, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
🇺🇸
Miami, Florida, United States
Pali Momi Medical Center
🇺🇸
'Aiea, Hawaii, United States
Maui Memorial Medical Center
🇺🇸
Wailuku, Hawaii, United States
Graham Hospital Association
🇺🇸
Canton, Illinois, United States
Illinois CancerCare-Canton
🇺🇸
Canton, Illinois, United States
Illinois CancerCare-Carthage
🇺🇸
Carthage, Illinois, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Presence Resurrection Medical Center
🇺🇸
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
🇺🇸
Chicago, Illinois, United States
Decatur Memorial Hospital
🇺🇸
Decatur, Illinois, United States
Heartland Cancer Research NCORP
🇺🇸
Decatur, Illinois, United States
Eureka Hospital
🇺🇸
Eureka, Illinois, United States
Illinois CancerCare-Eureka
🇺🇸
Eureka, Illinois, United States
NorthShore University HealthSystem-Evanston Hospital
🇺🇸
Evanston, Illinois, United States
Galesburg Cottage Hospital
🇺🇸
Galesburg, Illinois, United States
Illinois CancerCare-Cottage
🇺🇸
Galesburg, Illinois, United States
Illinois CancerCare-Galesburg
🇺🇸
Galesburg, Illinois, United States
Mason District Hospital
🇺🇸
Havana, Illinois, United States
Hinsdale Hematology Oncology Associates Incorporated
🇺🇸
Hinsdale, Illinois, United States
Sudarshan K Sharma MD Limited-Gynecologic Oncology
🇺🇸
Hinsdale, Illinois, United States
Illinois CancerCare-Macomb
🇺🇸
Macomb, Illinois, United States
Mcdonough District Hospital
🇺🇸
Macomb, Illinois, United States
Loyola University Medical Center
🇺🇸
Maywood, Illinois, United States
Holy Family Medical Center
🇺🇸
Monmouth, Illinois, United States
Illinois CancerCare-Monmouth
🇺🇸
Monmouth, Illinois, United States
Bromenn Regional Medical Center
🇺🇸
Normal, Illinois, United States
Community Cancer Center Foundation
🇺🇸
Normal, Illinois, United States
Illinois CancerCare-Community Cancer Center
🇺🇸
Normal, Illinois, United States
Illinois CancerCare-Ottawa Clinic
🇺🇸
Ottawa, Illinois, United States
Advocate Lutheran General Hospital
🇺🇸
Park Ridge, Illinois, United States
Ottawa Regional Hospital and Healthcare Center
🇺🇸
Ottawa, Illinois, United States
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
🇺🇸
Pekin, Illinois, United States
Pekin Hospital
🇺🇸
Pekin, Illinois, United States
Proctor Hospital
🇺🇸
Peoria, Illinois, United States
Methodist Medical Center of Illinois
🇺🇸
Peoria, Illinois, United States
OSF Saint Francis Medical Center
🇺🇸
Peoria, Illinois, United States
Illinois CancerCare-Peru
🇺🇸
Peru, Illinois, United States
Illinois Valley Hospital
🇺🇸
Peru, Illinois, United States
Illinois CancerCare-Princeton
🇺🇸
Princeton, Illinois, United States
Perry Memorial Hospital
🇺🇸
Princeton, Illinois, United States
Illinois CancerCare-Spring Valley
🇺🇸
Spring Valley, Illinois, United States
Memorial Medical Center
🇺🇸
Springfield, Illinois, United States
Northwestern Medicine Cancer Center Warrenville
🇺🇸
Warrenville, Illinois, United States
Northwestern Medicine Central DuPage Hospital
🇺🇸
Winfield, Illinois, United States
Elkhart Clinic
🇺🇸
Elkhart, Indiana, United States
Elkhart General Hospital
🇺🇸
Elkhart, Indiana, United States
Michiana Hematology Oncology PC-Elkhart
🇺🇸
Elkhart, Indiana, United States
Medical Oncology and Hematology Associates-West Des Moines
🇺🇸
Clive, Iowa, United States
Michiana Hematology Oncology PC-Westville
🇺🇸
Westville, Indiana, United States
University of Iowa/Holden Comprehensive Cancer Center
🇺🇸
Iowa City, Iowa, United States
Cancer Center of Kansas - El Dorado
🇺🇸
El Dorado, Kansas, United States
Cancer Center of Kansas - Fort Scott
🇺🇸
Fort Scott, Kansas, United States
Hematology/Oncology Clinic PLLC
🇺🇸
Baton Rouge, Louisiana, United States
Cancer Center of Kansas - Salina
🇺🇸
Salina, Kansas, United States
Greater Baltimore Medical Center
🇺🇸
Baltimore, Maryland, United States
Sinai Hospital of Baltimore
🇺🇸
Baltimore, Maryland, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
🇺🇸
Baltimore, Maryland, United States
Holy Cross Hospital
🇺🇸
Silver Spring, Maryland, United States
Maryland Oncology Hematology PA-Aquilino Cancer Center
🇺🇸
Rockville, Maryland, United States
Mercy Health Saint Mary's
🇺🇸
Grand Rapids, Michigan, United States
Allegiance Health
🇺🇸
Jackson, Michigan, United States
West Michigan Cancer Center
🇺🇸
Kalamazoo, Michigan, United States
Sparrow Hospital
🇺🇸
Lansing, Michigan, United States
Mercy Health Mercy Campus
🇺🇸
Muskegon, Michigan, United States
Lakeland Hospital Niles
🇺🇸
Niles, Michigan, United States
Lake Huron Medical Center
🇺🇸
Port Huron, Michigan, United States
Saint Joseph Mercy Oakland
🇺🇸
Pontiac, Michigan, United States
William Beaumont Hospital-Royal Oak
🇺🇸
Royal Oak, Michigan, United States
Ascension Saint Mary's Hospital
🇺🇸
Rhinelander, Wisconsin, United States
Lakeland Medical Center Saint Joseph
🇺🇸
Saint Joseph, Michigan, United States
Ascension Providence Hospitals - Southfield
🇺🇸
Southfield, Michigan, United States
Marie Yeager Cancer Center
🇺🇸
Saint Joseph, Michigan, United States
Munson Medical Center
🇺🇸
Traverse City, Michigan, United States
Saint John Macomb-Oakland Hospital
🇺🇸
Warren, Michigan, United States
Metro Health Hospital
🇺🇸
Wyoming, Michigan, United States
Essentia Health Saint Joseph's Medical Center
🇺🇸
Brainerd, Minnesota, United States
Mercy Hospital
🇺🇸
Scranton, Pennsylvania, United States
Miller-Dwan Hospital
🇺🇸
Duluth, Minnesota, United States
Fairview Southdale Hospital
🇺🇸
Edina, Minnesota, United States
Unity Hospital
🇺🇸
Fridley, Minnesota, United States
Hutchinson Area Health Care
🇺🇸
Hutchinson, Minnesota, United States
Minnesota Oncology Hematology PA-Maplewood
🇺🇸
Maplewood, Minnesota, United States
North Memorial Medical Health Center
🇺🇸
Robbinsdale, Minnesota, United States
Saint Cloud Hospital
🇺🇸
Saint Cloud, Minnesota, United States
Park Nicollet Frauenshuh Cancer Center
🇺🇸
Saint Louis Park, Minnesota, United States
Regions Hospital
🇺🇸
Saint Paul, Minnesota, United States
United Hospital
🇺🇸
Saint Paul, Minnesota, United States
Saint Francis Regional Medical Center
🇺🇸
Shakopee, Minnesota, United States
Lakeview Hospital
🇺🇸
Stillwater, Minnesota, United States
Rice Memorial Hospital
🇺🇸
Willmar, Minnesota, United States
Minnesota Oncology Hematology PA-Woodbury
🇺🇸
Woodbury, Minnesota, United States
University of Missouri - Ellis Fischel
🇺🇸
Columbia, Missouri, United States
Saint Louis University Hospital
🇺🇸
Saint Louis, Missouri, United States
Cancer Research for the Ozarks NCORP
🇺🇸
Springfield, Missouri, United States
Billings Clinic Cancer Center
🇺🇸
Billings, Montana, United States
Northern Rockies Radiation Oncology Center
🇺🇸
Billings, Montana, United States
Saint Vincent Healthcare
🇺🇸
Billings, Montana, United States
Montana Cancer Consortium NCORP
🇺🇸
Billings, Montana, United States
Bozeman Deaconess Hospital
🇺🇸
Bozeman, Montana, United States
Saint James Community Hospital and Cancer Treatment Center
🇺🇸
Butte, Montana, United States
Great Falls Clinic
🇺🇸
Great Falls, Montana, United States
Berdeaux, Donald MD (UIA Investigator)
🇺🇸
Great Falls, Montana, United States
Northern Montana Hospital
🇺🇸
Havre, Montana, United States
Saint Peter's Community Hospital
🇺🇸
Helena, Montana, United States
Glacier Oncology PLLC
🇺🇸
Kalispell, Montana, United States
Kalispell Medical Oncology
🇺🇸
Kalispell, Montana, United States
Saint Patrick Hospital - Community Hospital
🇺🇸
Missoula, Montana, United States
Kalispell Regional Medical Center
🇺🇸
Kalispell, Montana, United States
Montana Cancer Specialists
🇺🇸
Missoula, Montana, United States
Community Medical Hospital
🇺🇸
Missoula, Montana, United States
Walter Reed National Military Medical Center
🇺🇸
Bethesda, Maryland, United States
Guardian Oncology and Center for Wellness
🇺🇸
Missoula, Montana, United States
Mayo Clinic in Rochester
🇺🇸
Rochester, Minnesota, United States
Nebraska Methodist Hospital
🇺🇸
Omaha, Nebraska, United States
CHI Health Good Samaritan
🇺🇸
Kearney, Nebraska, United States
Women's Cancer Center of Nevada
🇺🇸
Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center
🇺🇸
Lebanon, New Hampshire, United States
Center of Hope at Renown Medical Center
🇺🇸
Reno, Nevada, United States
Norris Cotton Cancer Center-Manchester
🇺🇸
Manchester, New Hampshire, United States
Renown Regional Medical Center
🇺🇸
Reno, Nevada, United States
Cooper Hospital University Medical Center
🇺🇸
Camden, New Jersey, United States
Hunterdon Medical Center
🇺🇸
Flemington, New Jersey, United States
Hackensack University Medical Center
🇺🇸
Hackensack, New Jersey, United States
Aurora Saint Luke's Medical Center
🇺🇸
Milwaukee, Wisconsin, United States
Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Morristown Medical Center
🇺🇸
Morristown, New Jersey, United States
Virtua Memorial
🇺🇸
Mount Holly, New Jersey, United States
Valley Hospital
🇺🇸
Ridgewood, New Jersey, United States
Overlook Hospital
🇺🇸
Summit, New Jersey, United States
Virtua Voorhees
🇺🇸
Voorhees, New Jersey, United States
University of New Mexico Cancer Center
🇺🇸
Albuquerque, New Mexico, United States
Southwest Gynecologic Oncology Associates Inc
🇺🇸
Albuquerque, New Mexico, United States
Women's Cancer Care Associates LLC
🇺🇸
Albany, New York, United States
Island Gynecologic Oncology
🇺🇸
Brightwaters, New York, United States
New York Hospital Medical Center of Queens
🇺🇸
Fresh Meadows, New York, United States
Northwell Health NCORP
🇺🇸
Lake Success, New York, United States
North Shore University Hospital
🇺🇸
Manhasset, New York, United States
Long Island Jewish Medical Center
🇺🇸
New Hyde Park, New York, United States
Mount Kisco Medical Group
🇺🇸
Mount Kisco, New York, United States
Northern Westchester Hospital
🇺🇸
Mount Kisco, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
🇺🇸
New York, New York, United States
Mount Sinai Hospital
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States
NYP/Weill Cornell Medical Center
🇺🇸
New York, New York, United States
State University of New York Upstate Medical University
🇺🇸
Syracuse, New York, United States
Randolph Hospital
🇺🇸
Asheboro, North Carolina, United States
Stony Brook University Medical Center
🇺🇸
Stony Brook, New York, United States
Hope Women's Cancer Centers-Asheville
🇺🇸
Asheville, North Carolina, United States
Carolinas Medical Center/Levine Cancer Institute
🇺🇸
Charlotte, North Carolina, United States
Cone Health Cancer Center
🇺🇸
Greensboro, North Carolina, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Duke Raleigh Hospital
🇺🇸
Raleigh, North Carolina, United States
Annie Penn Memorial Hospital
🇺🇸
Reidsville, North Carolina, United States
Summa Health System - Akron Campus
🇺🇸
Akron, Ohio, United States
Cleveland Clinic Akron General
🇺🇸
Akron, Ohio, United States
Summa Health System - Barberton Campus
🇺🇸
Barberton, Ohio, United States
Cleveland Clinic Mercy Hospital
🇺🇸
Canton, Ohio, United States
Aultman Health Foundation
🇺🇸
Canton, Ohio, United States
University of Cincinnati/Barrett Cancer Center
🇺🇸
Cincinnati, Ohio, United States
MetroHealth Medical Center
🇺🇸
Cleveland, Ohio, United States
Cleveland Clinic Cancer Center/Fairview Hospital
🇺🇸
Cleveland, Ohio, United States
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
🇺🇸
Columbus, Ohio, United States
Riverside Methodist Hospital
🇺🇸
Columbus, Ohio, United States
Columbus NCI Community Oncology Research Program
🇺🇸
Columbus, Ohio, United States
Grant Medical Center
🇺🇸
Columbus, Ohio, United States
Grandview Hospital
🇺🇸
Dayton, Ohio, United States
Good Samaritan Hospital - Dayton
🇺🇸
Dayton, Ohio, United States
Miami Valley Hospital
🇺🇸
Dayton, Ohio, United States
Dayton NCI Community Oncology Research Program
🇺🇸
Dayton, Ohio, United States
Grady Memorial Hospital
🇺🇸
Delaware, Ohio, United States
Miami Valley Hospital North
🇺🇸
Dayton, Ohio, United States
Blanchard Valley Hospital
🇺🇸
Findlay, Ohio, United States
Wayne Hospital
🇺🇸
Greenville, Ohio, United States
Atrium Medical Center-Middletown Regional Hospital
🇺🇸
Franklin, Ohio, United States
Fairfield Medical Center
🇺🇸
Lancaster, Ohio, United States
Hillcrest Hospital Cancer Center
🇺🇸
Mayfield Heights, Ohio, United States
UH Seidman Cancer Center at Lake Health Mentor Campus
🇺🇸
Mentor, Ohio, United States
Knox Community Hospital
🇺🇸
Mount Vernon, Ohio, United States
Licking Memorial Hospital
🇺🇸
Newark, Ohio, United States
Springfield Regional Medical Center
🇺🇸
Springfield, Ohio, United States
Southern Ohio Medical Center
🇺🇸
Portsmouth, Ohio, United States
University of Toledo
🇺🇸
Toledo, Ohio, United States
Saint Ann's Hospital
🇺🇸
Westerville, Ohio, United States
Wright-Patterson Medical Center
🇺🇸
Wright-Patterson Air Force Base, Ohio, United States
Genesis Healthcare System Cancer Care Center
🇺🇸
Zanesville, Ohio, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
🇺🇸
Tulsa, Oklahoma, United States
University of Oklahoma Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
Legacy Good Samaritan Hospital and Medical Center
🇺🇸
Portland, Oregon, United States
Abington Memorial Hospital
🇺🇸
Abington, Pennsylvania, United States
Saint Luke's University Hospital-Bethlehem Campus
🇺🇸
Bethlehem, Pennsylvania, United States
Lehigh Valley Hospital-Cedar Crest
🇺🇸
Allentown, Pennsylvania, United States
Geisinger Medical Center
🇺🇸
Danville, Pennsylvania, United States
Geisinger Medical Center-Cancer Center Hazleton
🇺🇸
Hazleton, Pennsylvania, United States
Penn State Milton S Hershey Medical Center
🇺🇸
Hershey, Pennsylvania, United States
Pennsylvania Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Temple University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
UPMC-Magee Womens Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
Phoenixville Hospital
🇺🇸
Phoenixville, Pennsylvania, United States
Geisinger Medical Group
🇺🇸
State College, Pennsylvania, United States
Scranton Hematology Oncology
🇺🇸
Scranton, Pennsylvania, United States
WellSpan Health-York Hospital
🇺🇸
York, Pennsylvania, United States
AnMed Health Hospital
🇺🇸
Anderson, South Carolina, United States
AnMed Health Cancer Center
🇺🇸
Anderson, South Carolina, United States
Prisma Health Cancer Institute - Spartanburg
🇺🇸
Boiling Springs, South Carolina, United States
Prisma Health Cancer Institute - Easley
🇺🇸
Easley, South Carolina, United States
Greenville Health System Cancer Institute-Andrews
🇺🇸
Greenville, South Carolina, United States
Saint Francis Hospital
🇺🇸
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Butternut
🇺🇸
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Faris
🇺🇸
Greenville, South Carolina, United States
Prisma Health Greenville Memorial Hospital
🇺🇸
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Eastside
🇺🇸
Greenville, South Carolina, United States
Self Regional Healthcare
🇺🇸
Greenwood, South Carolina, United States
Prisma Health Cancer Institute - Greer
🇺🇸
Greer, South Carolina, United States
Prisma Health Cancer Institute - Seneca
🇺🇸
Seneca, South Carolina, United States
Spartanburg Medical Center
🇺🇸
Spartanburg, South Carolina, United States
Avera Cancer Institute
🇺🇸
Sioux Falls, South Dakota, United States
Sanford USD Medical Center - Sioux Falls
🇺🇸
Sioux Falls, South Dakota, United States
University of Tennessee - Knoxville
🇺🇸
Knoxville, Tennessee, United States
Vanderbilt University/Ingram Cancer Center
🇺🇸
Nashville, Tennessee, United States
Parkland Memorial Hospital
🇺🇸
Dallas, Texas, United States
UT Southwestern/Simmons Cancer Center-Dallas
🇺🇸
Dallas, Texas, United States
Brooke Army Medical Center
🇺🇸
Fort Sam Houston, Texas, United States
Baylor All Saints Medical Center at Fort Worth
🇺🇸
Fort Worth, Texas, United States
Lyndon Baines Johnson General Hospital
🇺🇸
Houston, Texas, United States
Houston Methodist Hospital
🇺🇸
Houston, Texas, United States
Colorado Gynecologic Oncology Group
🇺🇸
Aurora, Colorado, United States
University of Colorado Hospital
🇺🇸
Aurora, Colorado, United States
Scott and White Memorial Hospital
🇺🇸
Temple, Texas, United States
Wilford Hall Medical Center
🇺🇸
Lackland Air Force Base, Texas, United States
McKay-Dee Hospital Center
🇺🇸
Ogden, Utah, United States
Delbert Day Cancer Institute at PCRMC
🇺🇸
Rolla, Missouri, United States
Saint Luke's Hospital
🇺🇸
Chesterfield, Missouri, United States
Mercy Hospital Springfield
🇺🇸
Springfield, Missouri, United States
CoxHealth South Hospital
🇺🇸
Springfield, Missouri, United States
Marshfield Medical Center-Rice Lake
🇺🇸
Rice Lake, Wisconsin, United States
Aurora West Allis Medical Center
🇺🇸
West Allis, Wisconsin, United States
Marshfield Clinic - Wisconsin Rapids Center
🇺🇸
Wisconsin Rapids, Wisconsin, United States
Fairview Ridges Hospital
🇺🇸
Burnsville, Minnesota, United States
Essentia Health Saint Mary's Medical Center
🇺🇸
Duluth, Minnesota, United States
Coborn Cancer Center at Saint Cloud Hospital
🇺🇸
Saint Cloud, Minnesota, United States
Ridgeview Medical Center
🇺🇸
Waconia, Minnesota, United States
Park Nicollet Clinic - Saint Louis Park
🇺🇸
Saint Louis Park, Minnesota, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Northwell Health/Center for Advanced Medicine
🇺🇸
Lake Success, New York, United States
Harrison HealthPartners Hematology and Oncology-Bremerton
🇺🇸
Bremerton, Washington, United States
New Hanover Regional Medical Center/Zimmer Cancer Center
🇺🇸
Wilmington, North Carolina, United States
Saint Joseph Medical Center
🇺🇸
Tacoma, Washington, United States
Memorial Hospital
🇺🇸
Carthage, Illinois, United States
Women's Cancer Associates
🇺🇸
Saint Petersburg, Florida, United States
Advocate Sherman Hospital
🇺🇸
Elgin, Illinois, United States
Saint Vincent Hospital and Health Care Center
🇺🇸
Indianapolis, Indiana, United States
Michiana Hematology Oncology PC-Mishawaka
🇺🇸
Mishawaka, Indiana, United States
Michiana Hematology Oncology PC-South Bend
🇺🇸
South Bend, Indiana, United States
The Community Hospital
🇺🇸
Munster, Indiana, United States
Saint Joseph Regional Medical Center-Mishawaka
🇺🇸
Mishawaka, Indiana, United States
South Bend Clinic
🇺🇸
South Bend, Indiana, United States
Commonwealth Hematology Oncology PC-Worcester
🇺🇸
Worcester, Massachusetts, United States
Spectrum Health Big Rapids Hospital
🇺🇸
Big Rapids, Michigan, United States
Wayne State University/Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
Hurley Medical Center
🇺🇸
Flint, Michigan, United States
Cancer Research Consortium of West Michigan NCORP
🇺🇸
Grand Rapids, Michigan, United States
Genesys Regional Medical Center-West Flint Campus
🇺🇸
Flint, Michigan, United States
Saint Mary Mercy Hospital
🇺🇸
Livonia, Michigan, United States
Bronson Methodist Hospital
🇺🇸
Kalamazoo, Michigan, United States
Borgess Medical Center
🇺🇸
Kalamazoo, Michigan, United States
Mary Rutan Hospital
🇺🇸
Bellefontaine, Ohio, United States
Marietta Memorial Hospital
🇺🇸
Marietta, Ohio, United States
Clinton Memorial Hospital
🇺🇸
Wilmington, Ohio, United States
Geisinger Wyoming Valley/Henry Cancer Center
🇺🇸
Wilkes-Barre, Pennsylvania, United States
PeaceHealth Medical Group PC
🇺🇸
Bellingham, Washington, United States
Skagit Valley Hospital Regional Cancer Care Center
🇺🇸
Mount Vernon, Washington, United States
Harrison HealthPartners Hematology and Oncology-Poulsbo
🇺🇸
Poulsbo, Washington, United States
MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
🇺🇸
Spokane, Washington, United States
Olympic Medical Cancer Care Center
🇺🇸
Sequim, Washington, United States
Providence Saint Mary Regional Cancer Center
🇺🇸
Walla Walla, Washington, United States
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
🇺🇸
Yakima, Washington, United States
Marshfield Clinic Cancer Center at Sacred Heart
🇺🇸
Eau Claire, Wisconsin, United States
Marshfield Clinic-Chippewa Center
🇺🇸
Chippewa Falls, Wisconsin, United States
Green Bay Oncology at Saint Vincent Hospital
🇺🇸
Green Bay, Wisconsin, United States
Saint Vincent Hospital Cancer Center Green Bay
🇺🇸
Green Bay, Wisconsin, United States
Green Bay Oncology Limited at Saint Mary's Hospital
🇺🇸
Green Bay, Wisconsin, United States
Marshfield Medical Center-Marshfield
🇺🇸
Marshfield, Wisconsin, United States
Ascension Columbia Saint Mary's Hospital - Milwaukee
🇺🇸
Milwaukee, Wisconsin, United States
Aurora Sinai Medical Center
🇺🇸
Milwaukee, Wisconsin, United States
Ascension Columbia Saint Mary's Hospital Ozaukee
🇺🇸
Mequon, Wisconsin, United States
Marshfield Clinic-Minocqua Center
🇺🇸
Minocqua, Wisconsin, United States
Aurora Medical Center in Summit
🇺🇸
Summit, Wisconsin, United States
Ascension Saint Michael's Hospital
🇺🇸
Stevens Point, Wisconsin, United States
Marshfield Medical Center - Weston
🇺🇸
Weston, Wisconsin, United States
University of California Davis Comprehensive Cancer Center
🇺🇸
Sacramento, California, United States
Sutter Medical Center Sacramento
🇺🇸
Sacramento, California, United States
Saint Joseph Mercy Hospital
🇺🇸
Ann Arbor, Michigan, United States
Michigan Cancer Research Consortium NCORP
🇺🇸
Ann Arbor, Michigan, United States
Southeast Clinical Oncology Research Consortium NCORP
🇺🇸
Winston-Salem, North Carolina, United States
Wake Forest University Health Sciences
🇺🇸
Winston-Salem, North Carolina, United States
Pacific Gynecology Specialists
🇺🇸
Seattle, Washington, United States
Northern Indiana Cancer Research Consortium
🇺🇸
South Bend, Indiana, United States
Marshfield Medical Center
🇺🇸
Marshfield, Wisconsin, United States
Michiana Hematology Oncology PC-Plymouth
🇺🇸
Plymouth, Indiana, United States
Beaumont Hospital - Dearborn
🇺🇸
Dearborn, Michigan, United States
Cancer Institutes of Washington PLLC
🇺🇸
Yakima, Washington, United States
Vince Lombardi Cancer Clinic-Two Rivers
🇺🇸
Two Rivers, Wisconsin, United States
Henry Ford Hospital
🇺🇸
Detroit, Michigan, United States
Ascension Saint John Hospital
🇺🇸
Detroit, Michigan, United States
Kettering Medical Center
🇺🇸
Kettering, Ohio, United States
MultiCare Tacoma General Hospital
🇺🇸
Tacoma, Washington, United States
The Women's Oncology Center
🇺🇸
Saint Louis, Missouri, United States
UMass Memorial Medical Center - University Campus
🇺🇸
Worcester, Massachusetts, United States
AdventHealth Orlando
🇺🇸
Orlando, Florida, United States
Orlando Health Cancer Institute
🇺🇸
Orlando, Florida, United States
Norton Hospital Pavilion and Medical Campus
🇺🇸
Louisville, Kentucky, United States
Tulane University Health Sciences Center
🇺🇸
New Orleans, Louisiana, United States
Ochsner Medical Center Jefferson
🇺🇸
New Orleans, Louisiana, United States
UNC Lineberger Comprehensive Cancer Center
🇺🇸
Chapel Hill, North Carolina, United States
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
Virginia Commonwealth University/Massey Cancer Center
🇺🇸
Richmond, Virginia, United States
University of Hawaii Cancer Center
🇺🇸
Honolulu, Hawaii, United States
The Cancer Center of Hawaii-Liliha
🇺🇸
Honolulu, Hawaii, United States
Kapiolani Medical Center for Women and Children
🇺🇸
Honolulu, Hawaii, United States
Mercy Capitol
🇺🇸
Des Moines, Iowa, United States
Iowa-Wide Oncology Research Coalition NCORP
🇺🇸
Des Moines, Iowa, United States
Hawaii Cancer Care Inc - Waterfront Plaza
🇺🇸
Honolulu, Hawaii, United States
Queen's Cancer Center - Kuakini
🇺🇸
Honolulu, Hawaii, United States
Iowa Methodist Medical Center
🇺🇸
Des Moines, Iowa, United States
Queen's Medical Center
🇺🇸
Honolulu, Hawaii, United States
Straub Clinic and Hospital
🇺🇸
Honolulu, Hawaii, United States
Mercy Medical Center - Des Moines
🇺🇸
Des Moines, Iowa, United States
Medical Oncology and Hematology Associates-Des Moines
🇺🇸
Des Moines, Iowa, United States
Medical Oncology and Hematology Associates-Laurel
🇺🇸
Des Moines, Iowa, United States
Iowa Lutheran Hospital
🇺🇸
Des Moines, Iowa, United States
Baptist Health Lexington
🇺🇸
Lexington, Kentucky, United States
University of Kentucky/Markey Cancer Center
🇺🇸
Lexington, Kentucky, United States
Montefiore Medical Center-Einstein Campus
🇺🇸
Bronx, New York, United States
University of Wisconsin Hospital and Clinics
🇺🇸
Madison, Wisconsin, United States
Spectrum Health at Butterworth Campus
🇺🇸
Grand Rapids, Michigan, United States
Cancer Center of Kansas-Kingman
🇺🇸
Kingman, Kansas, United States
Cancer Center of Kansas - Newton
🇺🇸
Newton, Kansas, United States
NYU Winthrop Hospital
🇺🇸
Mineola, New York, United States
Cancer Center of Kansas - Parsons
🇺🇸
Parsons, Kansas, United States
Saint Margaret's Hospital
🇺🇸
Spring Valley, Illinois, United States
Chester County Hospital
🇺🇸
West Chester, Pennsylvania, United States

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts